<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risk assessment of adults with chemotherapy-induced neutropenia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risk assessment of adults with chemotherapy-induced neutropenia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Risk assessment of adults with chemotherapy-induced neutropenia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Wingard, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Bow, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H608695659"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cancer patients receiving systemic antineoplastic therapy sufficient to adversely affect myelopoiesis and the developmental integrity of the gastrointestinal mucosa are at risk for invasive infection due to colonizing bacteria and/or fungi that translocate across intestinal mucosal surfaces damaged by cytotoxic therapy. Since the magnitude of the neutrophil-mediated component of the inflammatory response may be muted in neutropenic patients [<a href="#rid1">1</a>], a fever may be the earliest and only sign of infection.</p><p>It is critical to recognize neutropenic fever early and to initiate empiric systemic antibacterial therapy promptly to avoid progression to a sepsis syndrome and possibly death. It is also important to assess the risk for serious complications that may develop in patients with neutropenic fever, since this assessment will dictate the approach to therapy, including the need for inpatient admission, intravenous antibiotics, and prolonged hospitalization [<a href="#rid2">2</a>].</p><p>This topic will provide an overview of the risk assessment for patients with neutropenic fever. An overview of neutropenic fever syndromes and the prevention and treatment of neutropenic fever syndromes in cancer patients at high and low risk for serious complications are presented separately; the diagnostic approach to patients presenting with neutropenic fever is also discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults"</a> and  <a class="medical medical_review" href="/z/d/html/16141.html" rel="external">"Prophylaxis of invasive fungal infections in adults with hematologic malignancies"</a> and  <a class="medical medical_review" href="/z/d/html/16534.html" rel="external">"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a> and  <a class="medical medical_review" href="/z/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a> and  <a class="medical medical_review" href="/z/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever"</a>.)</p><p class="headingAnchor" id="H1025172"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H1025440"><span class="h2">Fever</span><span class="headingEndMark"> — </span>Fever in neutropenic patients is defined as a single oral temperature of ≥38.3°C (101°F) or a temperature of ≥38°C (100.4°F) sustained over a one-hour period [<a href="#rid2">2</a>]. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes", section on 'Definitions'</a>.)</p><p class="headingAnchor" id="H1025447"><span class="h2">Neutropenia</span><span class="headingEndMark"> — </span>The definition of neutropenia varies from institution to institution, but neutropenia is usually defined as an absolute neutrophil count (ANC) &lt;1500 or 1000 cells/microL and severe neutropenia as an ANC &lt;500 cells/microL or an ANC that is expected to decrease to &lt;500 cells/microL over the next 48 hours [<a href="#rid2">2</a>]. Profound neutropenia is defined as an ANC &lt;100 cells/microL. The risk of clinically important infection rises as the neutrophil count falls below 500 cells/microL and is higher in those with a prolonged duration of severe neutropenia (&gt;7 days). The risk for bacteremic infection rises as the ANC falls below 100 cells/microL. For the purposes of this discussion, <strong>we are defining severe neutropenia as an ANC &lt;500 cells/microL.</strong></p><p>The ANC can be calculated by multiplying the total white blood cell count by the percentage of polymorphonuclear cells and bands (<a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">calculator 1</a>).</p><p>(See  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes", section on 'Neutropenia'</a> and  <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents", section on 'Definitions and normal values'</a> and  <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Definitions and normal values'</a>.)</p><p>Assessment of the risk of neutropenia prior to having the results of the white blood cell count and differential is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)", section on 'Risk of neutropenia'</a>.)</p><p class="headingAnchor" id="H608696315"><span class="h1">CATEGORIES OF RISK</span><span class="headingEndMark"> — </span>There are at least three different categories of risk relevant to the assessment of neutropenic patients:</p><p class="bulletIndent1"><span class="glyph">●</span>The risk of developing a neutropenic fever syndrome (see <a class="local">'Risk factors for neutropenic fever'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of developing medical complications as a result of the neutropenic fever syndrome that require hospitalization or prolong the length of stay (see <a class="local">'Risk of serious complications'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of nonresponse to the empiric antibacterial treatment for the neutropenic fever syndrome (see <a class="local">'Risk of treatment failure'</a> below)</p><p></p><p class="headingAnchor" id="H608696329"><span class="h1">RISK FACTORS FOR NEUTROPENIC FEVER</span><span class="headingEndMark"> — </span>The risk factors that are predictive of the development of a neutropenic fever syndrome can be divided into three subcategories: patient-related, disease-related, and treatment-related predictors [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H608696350"><span class="h2">Patient-related predictors</span><span class="headingEndMark"> — </span>Patient-related predictors of the development of neutropenic fever include:</p><p class="bulletIndent1"><span class="glyph">●</span>Age (particularly 65 years or more) [<a href="#rid4">4-7</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Female sex [<a href="#rid8">8</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>High body surface area [<a href="#rid9">9</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Poor performance status based upon pre-existing active cardiovascular, renal, endocrine, or pulmonary comorbidities [<a href="#rid8">8,10</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Poor nutritional status [<a href="#rid11">11</a>]</p><p></p><p class="headingAnchor" id="H608696358"><span class="h2">Disease-related predictors</span><span class="headingEndMark"> — </span>Disease-related predictors of the development of neutropenic fever include:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated lactate dehydrogenase (LDH) in patients with lymphoreticular diseases [<a href="#rid11">11</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Myelophthisis (bone marrow failure due to replacement of hematopoietic tissue by abnormal tissue) [<a href="#rid11">11</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphopenia [<a href="#rid12">12,13</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Advanced stage of the underlying malignancy [<a href="#rid5">5,8,14-16</a>]</p><p></p><p class="headingAnchor" id="H608696366"><span class="h2">Anti-cancer treatment-related predictors</span><span class="headingEndMark"> — </span>Anti–cancer treatment–related predictors of the development of neutropenic fever include:</p><p class="bulletIndent1"><span class="glyph">●</span>Administration of the planned dose intensity or dose density of high-dose chemotherapy regimens [<a href="#rid7">7,12,17-19</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure to administer prophylactic hematopoietic growth factor support to patients receiving high-risk regimens [<a href="#rid6">6,17</a>] (see  <a class="medical medical_review" href="/z/d/html/16889.html" rel="external">"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A number of variables have been associated with a higher risk for neutropenic fevers occurring during the first cycle of cancer chemotherapy with etoposide-based cytotoxic regimens including Karnofsky performance status (odds ratio [OR] 0.85, 95% CI 0.81-0.89), having three or more metastatic sites (OR 6.33, 95% CI 2.66-15.11), cardiovascular comorbidity (OR 4.88, 95% CI 1.74-13.67), recent surgery (OR 7.96, 95% CI 1.96-32.36), administration of alkylating agents (OR 4.50, 95% CI 1.10-18.48), total bilirubin ≥25 umol/L (OR 11.42, 95% CI 4.00-32.61), and absolute lymphocyte count of less than 0.7 x 10<sup>9</sup>/L (OR 4.22, 95% CI 2.00-9.75) [<a href="#rid20">20</a>]. </p><p></p><p class="headingAnchor" id="H608696374"><span class="h1">RISK OF SERIOUS COMPLICATIONS</span><span class="headingEndMark"> — </span>This risk assessment dictates the approach to therapy, including the need for inpatient admission, intravenous (IV) antibiotics, and prolonged hospitalization  (<a class="graphic graphic_table graphicRef67027" href="/z/d/graphic/67027.html" rel="external">table 1</a>). High-risk patients require admission to hospital for IV antibiotics and often require a prolonged length of stay. By contrast, low-risk patients may be treated with oral antibiotics as outpatients after a brief period of observation or a short hospital admission. (See  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a> and  <a class="medical medical_review" href="/z/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a>.) </p><p>Validated scoring systems used to estimate the risk for medical complications include the Talcott rules [<a href="#rid21">21</a>], the Multinational Association for Supportive Care in Cancer (MASCC) score [<a href="#rid14">14</a>], and the Clinical Index of Stable Febrile Neutropenia (CISNE) score [<a href="#rid22">22</a>].</p><p>The risk assessment should also take into account infection due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The most frequent presenting symptoms of coronavirus disease 2019 (COVID-19) include fever, cough, and difficulty in breathing, which overlap with common presentations of a spectrum of infectious and noninfectious respiratory syndromes among cancer patients. Although cancer patients are thought not to be greater risk for contracting COVID-19, the risk for more severe COVID-19-related sequelae appears to be greater. Further, the risk of SARS-CoV-2 transmission from patient to heath care provider must also be considered and guide the use of personal protective equipment and isolation procedures [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/128993.html" rel="external">"COVID-19: Considerations in patients with cancer"</a>.)</p><p class="headingAnchor" id="H347726051"><span class="h2">Our definitions of low-risk and high-risk patients</span><span class="headingEndMark"> — </span>We define low-risk and high-risk patients as follows; it should be noted that the Infectious Diseases Society of America (IDSA) and National Comprehensive Cancer Network (NCCN) use different definitions in their guidelines (see <a class="local">'IDSA risk assessment'</a> below and <a class="local">'NCCN risk assessment'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Low-risk patients are defined as those who are expected to be severely neutropenic (absolute neutrophil count [ANC] &lt;500 cells/microL) for ≤7 days and who have no active comorbidities or evidence of significant hepatic or renal dysfunction. This group of patients has been well studied in randomized trials and has been shown to be at low risk for serious complications [<a href="#rid2">2</a>]. Most patients receiving chemotherapy for solid tumors are considered to be low risk for complications requiring hospitalization or prolonging hospitalization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We define high-risk patients as those who are expected to be neutropenic (ANC &lt;500 cells/microL) for &gt;7 days. Patients with neutropenic fever who have ongoing comorbidities or evidence of significant hepatic or renal dysfunction are also considered to be high risk, regardless of the duration of neutropenia. Other criteria that confer a high-risk status can be found in the table  (<a class="graphic graphic_table graphicRef67027" href="/z/d/graphic/67027.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">Some experts have defined high-risk patients as those expected to have profound neutropenia (ANC ≤100 cells/microL) for &gt;7 days based on experience that such patients are the most likely to have life-threatening complications [<a href="#rid2">2,24,25</a>]. However, formal studies to clearly differentiate between patients with an ANC &lt;500 cells/microL and ≤100 cells/microL are lacking. For the purposes of this discourse, we will combine these groups. Profound prolonged neutropenia (ie, ANC ≤100 cells/microL expected to last &gt;7 days) is most likely to occur in the pre-engraftment phase of myeloablative hematopoietic cell transplantation (HCT; particularly allogeneic) and in patients undergoing induction chemotherapy for acute leukemia.</p><p></p><p class="headingAnchor" id="H477942294"><span class="h2">Risk based on underlying disease</span><span class="headingEndMark"> — </span>Patients who are neutropenic as a result of induction chemotherapy for acute myelogenous leukemia or as part of the conditioning regimen for allogeneic HCT are at particularly high risk for serious infections  (<a class="graphic graphic_table graphicRef119454" href="/z/d/graphic/119454.html" rel="external">table 2</a>). Other factors that confer a high-risk status include oral and gastrointestinal mucositis, uncontrolled cancer, chronic obstructive pulmonary disease, poor functional status, and advanced age.</p><p>Patients undergoing autologous HCT or receiving consolidation chemotherapy for leukemia may also have prolonged periods of neutropenia but appear to be at somewhat lower risk, particularly if they are receiving prophylactic hematopoietic growth factors.</p><p>Patients with solid tumors are generally at low risk for serious infections.</p><p class="headingAnchor" id="H24666474"><span class="h2">Guidelines</span><span class="headingEndMark"> — </span>The IDSA, the European Society of Medical Oncology, the NCCN, and the American Society for Clinical Oncology (ASCO) recommend that an assessment of risk (high risk versus low risk) for neutropenic fever–related medical complications should be obtained at the time of the initial assessment of the neutropenic fever episode [<a href="#rid2">2,24,26,27</a>].</p><p>The IDSA and ASCO defined high-risk neutropenic patients as those with an ANC ≤100 cells/microL expected to last &gt;7 days or evidence of ongoing comorbid conditions or significant hepatic or renal dysfunction [<a href="#rid2">2,27</a>]. The NCCN has developed similar criteria but also includes an intermediate risk category [<a href="#rid24">24</a>]. In contrast with the IDSA, ASCO, and NCCN definitions, our definition of high-risk patients includes those who are expected to be neutropenic (ANC &lt;500 cells/microL) for &gt;7 days. (See <a class="local">'Our definitions of low-risk and high-risk patients'</a> above.)</p><p>The MASCC risk index is a validated tool for measuring the risk for neutropenic fever–related medical complications (<a class="calc calc_professional" href="/z/d/html/16931.html" rel="external">calculator 2</a>) [<a href="#rid14">14,28-30</a>]. The MASCC risk index may be used as an alternative to using clinical criteria to help in the selection of patients for whom outpatient oral initial empiric antibacterial therapy may be considered.</p><p class="headingAnchor" id="H608696409"><span class="h3">IDSA risk assessment</span><span class="headingEndMark"> — </span>The Infectious Diseases Society of America has developed criteria for defining neutropenic patients as high risk or low risk when they present with a fever [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H608696417"><span class="h4">High risk</span><span class="headingEndMark"> — </span>High-risk febrile neutropenic patients are defined as those with <strong>any</strong> of the following characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>ANC ≤100 cells/microL expected to last &gt;7 days <strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of ongoing comorbid conditions, such as (but not limited to):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamic instability</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral or gastrointestinal tract mucositis limiting swallowing or causing severe diarrhea</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal symptoms, such as abdominal pain, nausea and vomiting, or diarrhea</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic or mental status changes of new onset</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravascular catheter infection</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New pulmonary infiltrate or hypoxia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Underlying chronic lung disease <strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of hepatic insufficiency (defined as aminotransferase levels &gt;5 times normal values) or renal insufficiency (defined as a creatinine clearance &lt;30 mL/min) [<a href="#rid2">2</a>]</p><p></p><p>The ASCO/IDSA guidelines suggest that despite a low-risk MASCC score of ≥21, the presence of characteristics such as these should discourage outpatient care strategies [<a href="#rid27">27</a>].</p><p>Profound prolonged neutropenia (ANC ≤100 cells/microL expected to last &gt;7 days) is most likely to occur in the pre-engraftment phase of HCT (particularly allogeneic recipients receiving a myeloablative conditioning regimen) and in patients undergoing induction chemotherapy for acute leukemia.</p><p class="headingAnchor" id="H608696424"><span class="h4">Low risk</span><span class="headingEndMark"> — </span>Low-risk febrile neutropenic patients are expected to have a duration of neutropenia (ANC &lt;500 cells/microL) of 7 days or fewer and have no comorbidities or evidence of significant hepatic or renal dysfunction [<a href="#rid2">2</a>]. Most patients receiving chemotherapy for solid tumors are considered to be low risk for complications requiring hospitalization or prolonging hospitalization. Such patients would be represented among those satisfying the Talcott rule group IV or having a MASCC score ≥21 or CISNE score &lt;3.</p><p>Patients presenting with evidence of severe sepsis (sepsis syndrome with end-organ dysfunction) should be regarded as high risk and managed with intravenously administered initial empiric antibacterial therapy and hospitalization. Patients with evidence of septic shock should be managed in a critical care hospital environment based upon goal-directed therapy [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a> and  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p class="headingAnchor" id="H608696431"><span class="h3">NCCN risk assessment</span><span class="headingEndMark"> — </span>The National Comprehensive Cancer Network has developed criteria to categorize patients as high risk or low risk, which should be performed during the initial assessment [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H608696438"><span class="h4">High risk</span><span class="headingEndMark"> — </span>The NCCN categorizes febrile neutropenic patients as high risk if <strong>any</strong> of the following criteria are met [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Inpatient status at time of development of fever</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant medical comorbidity or presence of clinical instability</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticipated prolonged profound neutropenia (ANC ≤100 cells/microL expected to last &gt;7 days)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic insufficiency (defined as aminotransferase levels &gt;5 times normal values) or renal insufficiency (defined as a creatinine clearance &lt;30 mL/min)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Uncontrolled progressive cancer defined as any leukemic patient not in complete remission or any nonleukemic patient with evidence of disease progression after more than two courses of chemotherapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonia or other complex infection at clinical presentation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">Alemtuzumab</a> within the past two months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grade 3 or 4 mucositis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MASCC risk index score &lt;21 (<a class="calc calc_professional" href="/z/d/html/16931.html" rel="external">calculator 2</a>)</p><p></p><p class="headingAnchor" id="H608696445"><span class="h4">Low risk</span><span class="headingEndMark"> — </span>The NCCN categorizes febrile neutropenic patients as low risk for complications if they do not meet <strong>any</strong> of the high-risk criteria described above and if they meet most of the following criteria [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Outpatient status at time of development of fever</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No associated acute comorbid illness requiring inpatient hospitalization or close observation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticipated short duration of severe neutropenia (ANC ≤100 cells/microL expected to last 7 days or fewer)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Good performance status (Eastern Cooperative Oncology Group [ECOG] 0 to 1  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 3</a>))</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No hepatic insufficiency</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No renal insufficiency</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MASCC risk index score ≥21 (<a class="calc calc_professional" href="/z/d/html/16931.html" rel="external">calculator 2</a>) (see <a class="local">'MASCC score'</a> below)</p><p></p><p class="headingAnchor" id="H608696452"><span class="h4">Intermediate risk</span><span class="headingEndMark"> — </span>In addition to the categories of high risk and low risk described above, the NCCN defines febrile neutropenic patients to be intermediate risk for complications if <strong>any</strong> of the following criteria are met [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Autologous HCT</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphoma</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic lymphocytic leukemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple myeloma</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Purine analog therapy (see  <a class="medical medical_review" href="/z/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Purine analogs'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticipated duration of neutropenia of 7 to 10 days</p><p></p><p>The NCCN recommends consideration of fluoroquinolone prophylaxis for intermediate-risk patients. (See  <a class="medical medical_review" href="/z/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults"</a>.)</p><p class="headingAnchor" id="H418025383"><span class="h2">MASCC score</span><span class="headingEndMark"> — </span>The Multinational Association for Supportive Care in Cancer risk index is a validated tool for measuring the risk for neutropenic fever–related medical complications [<a href="#rid14">14,28-30,32</a>]. The MASCC risk index may be used as an alternative to the clinical risk assessments described above. (See <a class="local">'Our definitions of low-risk and high-risk patients'</a> above and <a class="local">'Guidelines'</a> above.)</p><p>Using the MASCC risk index, the following characteristics are assessed and given a weighted score (<a class="calc calc_professional" href="/z/d/html/16931.html" rel="external">calculator 2</a>) [<a href="#rid2">2,14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Burden of illness (the general clinical status of the patient at the time of presentation with neutropenic fever)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No or mild symptoms – 5</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate symptoms – 3</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe symptoms or moribund – 0</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No hypotension (systolic blood pressure &gt;90 mmHg) – 5</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No chronic obstructive pulmonary disease – 4</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Solid tumor or hematologic malignancy with no history of previous fungal infections – 4</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No dehydration requiring parenteral fluids – 3</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Outpatient status at the time of onset of the neutropenic fever syndrome – 3</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age &lt;60 years – 2</p><p></p><p>The maximum attainable score is 26. A score ≥21 predicts those patients at low risk for serious medical complications and those for whom outpatient management with an oral empiric antibacterial regimen may be safe and effective [<a href="#rid30">30</a>]. A score &lt;21 predicts those patients at high risk for serious medical complications (see <a class="local">'Serious medical complications'</a> below). The MASCC risk index has correctly classified low-risk and high-risk patients in 98 and 86 percent of cases, respectively, giving a sensitivity, specificity, and positive and negative predictive value of 95, 95, 98, and 86 percent, respectively [<a href="#rid29">29</a>].</p><p>The reclassification of patients with "complicated" infections (defined by presence of a visceral site of infection, sepsis syndrome, nonnecrotizing skin or soft tissue infection [SSTI] of &gt;5 cm diameter, necrotizing SSTI of any size, or oral mucositis [World Health Organization grade &gt;2]) as high risk for serious medical complications has further increased the predictive value of the model [<a href="#rid33">33</a>]. The misclassification rate has been 10 to 29 percent [<a href="#rid3">3</a>].</p><p>In addition, the MASCC risk index may predict the likelihood of death as follows [<a href="#rid28">28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>&lt;15: 29 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>≥15 but &lt;21: 9 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>≥21: 2 percent</p><p></p><p>A retrospective cohort study suggested that a mean C-reactive protein (CRP) concentration &gt;150 mg/L (&gt;15 mg/dL) together with a high-risk MASCC score is associated with a higher risk of 30-day all-cause mortality than a high-risk MASCC score and a mean CRP concentration &lt;150 mg/L (&lt;15 mg/dL; 36 versus 2 percent) [<a href="#rid34">34</a>]. In another study of 400 episodes of neutropenic fever in 355 patients, a baseline serum procalcitonin of ≥0.5 ng/mL, a MASCC score &lt;21, and a platelet count of &lt;100/microL were independent predictors of bacteremia [<a href="#rid35">35</a>]. Moreover, a baseline serum procalcitonin of ≥1.5 ng/mL and a MASCC score &lt;21 were independent predictors of septic shock, suggesting that the availability of these results at presentation can be used to help clinicians make informed decisions regarding patient disposition. Serum procalcitonin (&gt;0.25 ng/mL), serum lactate (&gt;2.2 mmol/L), and MASCC score (&lt;21) have been independent covariates of bloodstream infection in cancer patients presenting with febrile neutropenia [<a href="#rid36">36</a>].</p><p>One criticism of the MASCC risk index is the lack of a standardized definition of this criterion, "burden of febrile neutropenia," which might be confusing [<a href="#rid2">2</a>] or interpreted differently by different clinicians. Another important point is that the MASCC risk index does not include duration of neutropenia as a criterion, although this is considered an important predictor of risk [<a href="#rid2">2</a>].</p><p>Another criticism is that the MASCC risk index was developed using heterogeneous patient populations and that it may not perform optimally in all populations. As an example, in a retrospective study of outpatients with solid tumors who appeared to be clinically stable, the MASCC risk index had a low sensitivity to detect complications (36 percent) [<a href="#rid37">37</a>]. The low sensitivity was likely to be due to the fact that the patients were all outpatients and the rates of hypotension, dehydration, and invasive fungal infections were low; thus, only three criteria were present to make a prognostic distinction.</p><p class="headingAnchor" id="H418025409"><span class="h3">Serious medical complications</span><span class="headingEndMark"> — </span>The serious medical complications predicted by the MASCC risk index include [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension (defined by a systolic blood pressure &lt;90 mmHg or by the need for vasopressor support to maintain blood pressure)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory failure (defined by an arterial oxygen pressure &lt;60 mmHg while breathing room air or by the need for mechanical ventilation)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Admission to a critical care service</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated intravascular coagulation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of confusion, delirium, or altered mental state</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Development of congestive cardiac failure documented by chest imaging and that requires treatment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding diathesis sufficient to require blood cell transfusion</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Arrhythmia or electrocardiogram changes requiring treatment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal failure sufficient to require investigation and/or treatment with IV fluids, dialysis, or any other intervention</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other complications judged serious and clinically significant by the medical care team</p><p></p><p class="headingAnchor" id="H1765376824"><span class="h2">Clinical Index of Stable Febrile Neutropenia</span><span class="headingEndMark"> — </span>The Clinical Index of Stable Febrile Neutropenia (CISNE) is a validated scoring system that was developed to predict major complications in outpatients with solid tumors receiving mild- or moderate-intensity chemotherapy and who were experiencing a neutropenic fever syndrome but were clinically stable [<a href="#rid22">22</a>].</p><p>Points were assigned as follows in patients with any of the following variables associated with serious complications:</p><p class="bulletIndent1"><span class="glyph">●</span>Eastern Cooperative Oncology Group performance status ≥2  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 3</a>) – 2 points</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic obstructive pulmonary disease – 1 point</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic cardiovascular disease – 1 point</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mucositis of grade ≥2 – 1 point</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monocytes &lt;200/microL – 1 point</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stress-induced hyperglycemia – 2 points</p><p></p><p>Patients were then stratified into the following prognostic classes based upon their scores:</p><p class="bulletIndent1"><span class="glyph">●</span>Class I (low risk) – 0 points</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class II (intermediate risk) – 1 to 2 points</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class III (high risk) - ≥3 points</p><p></p><p>In the validation group, complication rates were 1.1 percent in class I patients, 6.2 percent in class II patients, and 36 percent in class III patients. Mortality rates were 0 percent in class I patients, 0 percent in class II patients, and 3.1 percent in class III patients. Using a cutoff of ≥3 points, for predicting major complications, the CISNE had sensitivity of 77.7 percent, specificity of 78.4 percent, positive predictive value of 36.1 percent, and negative predictive value of 95.7 percent. The predictive performance of the CISNE was better than that of the MASCC score, which is not surprising given the known limitations of the MASCC score in patients with solid tumors (see <a class="local">'MASCC score'</a> above). A subsequent study using a CISNE score cutoff of ≥1 points in febrile neutropenic patients presenting to two academic emergency departments similarly concluded that the CISNE score may be the best predictor for risk stratification in that setting [<a href="#rid38">38</a>]. A third study encompassing febrile neutropenic cancer patients from three tertiary cancer centers in South Korea, the United Kingdom, and the United States, 52 percent of whom had solid tumors, demonstrated a greater discriminating power for low-risk patients for the MASCC score (AUC 0.772; 95% CI 0.726-0.819) compared with the CISNE score (AUC 0.681; 95% CI 0.626-0.737) [<a href="#rid39">39</a>].</p><p>Experience tells us that outpatient management of febrile neutropenic patients at low-risk for complications is safe and effective but imperfect [<a href="#rid40">40</a>]. It seems clear that these predictive tools are useful; however, it remains unclear how they should be used: in isolation of one another or perhaps together in a sequence to provide a basis for informed clinical decisions.</p><p class="headingAnchor" id="H24657794"><span class="h2">Risk of sepsis</span><span class="headingEndMark"> — </span>Although the signs and symptoms of infection may be significantly muted in neutropenic patients [<a href="#rid1">1,41</a>], an early part of the clinical assessment at triage should include an examination for evidence of a systemic inflammatory response syndrome (SIRS) and a determination of the criteria for sepsis, severe sepsis, and septic shock [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis", section on 'Definitions'</a>.)</p><p>Patients presenting with evidence of new organ dysfunction (altered mental status, hypotension, hypoxia, or oliguria) should be managed emergently for severe sepsis. The following Algorithm provides a suggested time-dependent care pathway for neutropenic cancer patients presenting at an emergency triage facility based upon historical and observational clinical criteria assessable at presentation  (<a class="graphic graphic_algorithm graphicRef57616" href="/z/d/graphic/57616.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p class="headingAnchor" id="H608696459"><span class="h1">RISK OF TREATMENT FAILURE</span><span class="headingEndMark"> — </span>The risk of failure to respond to the initial empiric antibacterial therapy is a major risk that the clinician must consider. Treatment failure is a composite outcome that is defined by one or more of the following events occurring within 30 days of the start of treatment [<a href="#rid40">40,43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Death</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistence, progression, or recrudescence of signs and symptoms of infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modification of the initial empiric antibacterial regimen</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For outpatients, readmission to the hospital</p><p></p><p>Several factors influence the risk of treatment failure:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment failure is more likely among patients with documented infections, clinical or microbiologic, than for unexplained neutropenic fevers (39 versus 18 percent) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment failure occurs more often among high-risk patients than low-risk patients. As an example, patients with hematologic malignancies have a higher rate of treatment failure than those with solid tumors (44 versus 18 percent) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among febrile neutropenic patients at low risk for medical complications, the treatment failure rate is higher for adults compared with children (16 versus 5 percent) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delay in the institution of appropriate and effective antibacterial therapy [<a href="#rid45">45,46</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poor baseline performance status  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 3</a>) [<a href="#rid47">47</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure to administer guideline-driven initial empiric antibacterial therapy [<a href="#rid48">48</a>]</p><p></p><p>These observations underscore the prognostic importance of the underlying diagnosis, the risk category (high risk versus low risk), and the clinical characteristics of the neutropenic fever syndrome.</p><p>Outcomes are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)", section on 'Outcomes'</a> and  <a class="medical medical_review" href="/z/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications", section on 'Outcomes'</a>.)</p><p class="headingAnchor" id="H2042634491"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/89369.html" rel="external">"Patient education: Neutropenia and fever in people being treated for cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H235079179"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk categories</strong> − There are at least three different categories of risk relevant to the assessment of neutropenic patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The risk of developing a neutropenic fever syndrome (see <a class="local">'Risk factors for neutropenic fever'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The risk of developing medical complications as a result of the neutropenic fever syndrome that require hospitalization or prolong the length of stay (see <a class="local">'Risk of serious complications'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The risk of nonresponse to the empiric antibacterial treatment for the neutropenic fever syndrome (see <a class="local">'Risk of treatment failure'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> − The risk factors that are predictive of the development of a neutropenic fever syndrome can be divided into three subcategories: patient-related, disease-related, and treatment-related predictors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patient-related predictors include age (particularly 65 years or more), female sex, high body surface area, poor performance status  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 3</a>), and poor nutritional status.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Disease-related predictors include elevated lactate dehydrogenase in patients with lymphoreticular diseases, myelophthisis (bone marrow failure due to replacement of hematopoietic tissue by abnormal tissue), lymphopenia, and advanced stage of the underlying malignancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment-related predictors of neutropenic fever include administration of the planned dose intensity or dose density of high-dose chemotherapy regimens and failure to administer hematopoietic growth factor support to patients receiving high-risk regimens. (See <a class="local">'Risk factors for neutropenic fever'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk assessment</strong> − We recommend that all patients presenting with neutropenic fever undergo a risk assessment for serious complications, since this assessment will dictate the approach to therapy  (<a class="graphic graphic_table graphicRef67027" href="/z/d/graphic/67027.html" rel="external">table 1</a>). High-risk patients require admission to hospital for intravenous antibiotics and often require a prolonged length of stay. By contrast, low-risk patients may be treated with oral antibiotics as outpatients after a brief period of observation or a short hospital admission. (See <a class="local">'Risk of serious complications'</a> above and  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a> and  <a class="medical medical_review" href="/z/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High risk</strong> − We define high-risk patients as those who are expected to be severely neutropenic (absolute neutrophil count [ANC] &lt;500 cells/microL) for &gt;7 days. Patients with neutropenic fever who have ongoing comorbidities or evidence of significant hepatic or renal dysfunction are also considered to be high risk, regardless of the duration of neutropenia. Other criteria that confer a high-risk status can be found in the table  (<a class="graphic graphic_table graphicRef67027" href="/z/d/graphic/67027.html" rel="external">table 1</a>). (See <a class="local">'Our definitions of low-risk and high-risk patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low risk</strong> − Low-risk febrile neutropenic patients are expected to have a duration of neutropenia (ANC &lt;500 cells/microL) of 7 days or fewer and have no comorbidities or evidence of significant hepatic or renal dysfunction. These features are most commonly seen in patients with solid tumors. (See <a class="local">'Low risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MASCC risk index</strong> − The Multinational Association for Supportive Care in Cancer (MASCC) risk index is a validated tool for measuring the risk for neutropenic fever–related medical complications (<a class="calc calc_professional" href="/z/d/html/16931.html" rel="external">calculator 2</a>). A score of ≥21 predicts those patients at low risk for serious medical complications and those for whom outpatient management with an oral empiric antibacterial regimen may be safe and effective. A score of &lt;21 predicts those patients at high risk for serious medical complications. The MASCC risk index may be used in addition to the clinical criteria described above to help inform clinical decision-making. (See <a class="local">'MASCC score'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of treatment failure</strong> − Risk factors for treatment failure include the presence of a documented infection and high-risk status for serious complications (eg, hematologic malignancy). (See <a class="local">'Risk of treatment failure'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135:715.</a></li><li><a class="nounderline abstract_t">Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.</a></li><li class="breakAll">Bow EJ. The diagnostic approach to the febrile neutropaenic patient: Clinical considerations. In: Infections in Hematology, Maschmeyer G, Rolston K (Eds), Springer-Verlag, Heidelberg 2011.</li><li><a class="nounderline abstract_t">Fosså SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998; 16:716.</a></li><li><a class="nounderline abstract_t">Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 2001; 12:1359.</a></li><li><a class="nounderline abstract_t">Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 2005; 23:7974.</a></li><li><a class="nounderline abstract_t">Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005; 10:427.</a></li><li><a class="nounderline abstract_t">Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004; 22:4302.</a></li><li><a class="nounderline abstract_t">Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 2006; 14:901.</a></li><li><a class="nounderline abstract_t">Voog E, Bienvenu J, Warzocha K, et al. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J Clin Oncol 2000; 18:325.</a></li><li><a class="nounderline abstract_t">Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 37:351.</a></li><li><a class="nounderline abstract_t">Ray-Coquard I, Borg C, Bachelot T, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003; 88:181.</a></li><li><a class="nounderline abstract_t">Blay JY, Chauvin F, Le Cesne A, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996; 14:636.</a></li><li><a class="nounderline abstract_t">Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038.</a></li><li><a class="nounderline abstract_t">Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13:2688.</a></li><li><a class="nounderline abstract_t">von Minckwitz G, Schwenkglenks M, Skacel T, et al. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer 2009; 45:608.</a></li><li><a class="nounderline abstract_t">Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42:2433.</a></li><li><a class="nounderline abstract_t">Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008; 16:1299.</a></li><li><a class="nounderline abstract_t">Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33:3199.</a></li><li><a class="nounderline abstract_t">Zhu Y, Guo D, Kong X, et al. A Risk-Prediction Nomogram for Neutropenia or Febrile Neutropenia after Etoposide-Based Chemotherapy in Cancer Patients: A Retrospective Cohort Study. Pharmacology 2022; 107:69.</a></li><li><a class="nounderline abstract_t">Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10:316.</a></li><li><a class="nounderline abstract_t">Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol 2015; 33:465.</a></li><li><a class="nounderline abstract_t">Cooksley T, Font C, Scotte F, et al. Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Support Care Cancer 2021; 29:1129.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 2.2014. http://www.nccn.org (Accessed on November 06, 2014).</li><li><a class="nounderline abstract_t">Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31:794.</a></li><li><a class="nounderline abstract_t">de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 Suppl 5:v252.</a></li><li><a class="nounderline abstract_t">Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol 2018; 36:1443.</a></li><li><a class="nounderline abstract_t">Paesmans M, Klastersky J, Maertens J, et al. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer 2011; 19:1001.</a></li><li><a class="nounderline abstract_t">Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 2004; 12:555.</a></li><li><a class="nounderline abstract_t">Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006; 24:4129.</a></li><li><a class="nounderline abstract_t">Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296.</a></li><li><a class="nounderline abstract_t">Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2013; 21:1487.</a></li><li><a class="nounderline abstract_t">de Souza Viana L, Serufo JC, da Costa Rocha MO, et al. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2008; 16:841.</a></li><li><a class="nounderline abstract_t">Combariza JF, Lombana M, Pino LE, Arango M. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms. Support Care Cancer 2015; 23:1009.</a></li><li><a class="nounderline abstract_t">Ahn S, Lee YS, Lim KS, Lee JL. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer 2013; 21:2303.</a></li><li><a class="nounderline abstract_t">Chaftari P, Chaftari AM, Hachem R, et al. The role of procalcitonin in identifying high-risk cancer patients with febrile neutropenia: A useful alternative to the multinational association for supportive care in cancer score. Cancer Med 2021; 10:8475.</a></li><li><a class="nounderline abstract_t">Carmona-Bayonas A, Gómez J, González-Billalabeitia E, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer 2011; 105:612.</a></li><li><a class="nounderline abstract_t">Coyne CJ, Le V, Brennan JJ, et al. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department. Ann Emerg Med 2017; 69:755.</a></li><li><a class="nounderline abstract_t">Ahn S, Rice TW, Yeung SJ, Cooksley T. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents. Support Care Cancer 2018; 26:1465.</a></li><li><a class="nounderline abstract_t">Teuffel O, Ethier MC, Alibhai SM, et al. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 2011; 22:2358.</a></li><li><a class="nounderline abstract_t">Sickles EA, Young VM, Greene WH, Wiernik PH. Pneumonia in acute leukemia. Ann Intern Med 1973; 79:528.</a></li><li class="breakAll">Bell MS, Scullen P, McParlan D, et al. Neutropenic sepsis guidelines. Northern Ireland Cancer Network, Belfast 2010. p. 1-11.</li><li><a class="nounderline abstract_t">Vidal L, Paul M, Ben dor I, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 2004; 54:29.</a></li><li><a class="nounderline abstract_t">Vidal L, Paul M, Ben-Dor I, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2004; :CD003992.</a></li><li><a class="nounderline abstract_t">Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913.</a></li><li><a class="nounderline abstract_t">Kang CI, Chung DR, Ko KS, et al. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 2012; 91:115.</a></li><li><a class="nounderline abstract_t">Park CM, Koh Y, Jeon K, et al. Impact of Eastern Cooperative Oncology Group Performance Status on hospital mortality in critically ill patients. J Crit Care 2014; 29:409.</a></li><li><a class="nounderline abstract_t">Wright JD, Neugut AI, Ananth CV, et al. Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med 2013; 173:559.</a></li></ol></div><div id="topicVersionRevision">Topic 16888 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1052668" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical presentation of infection in granulocytopenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469362" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11762805" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16258098" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15967836" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk models for predicting chemotherapy-induced neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15381684" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16622653" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10637246" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10752986" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610500" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636781" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10944139" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7595726" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19110415" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16750358" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18351398" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26169616" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34673655" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A Risk-Prediction Nomogram for Neutropenia or Febrile Neutropenia after Etoposide-Based Chemotherapy in Cancer Patients: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732432" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25559804" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33230644" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33230644" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23319691" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20555092" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Management of febrile neutropenia: ESMO Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29461916" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20596732" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15197637" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16943529" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18158437" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23443617" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17960431" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25270848" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23519568" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34725958" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The role of procalcitonin in identifying high-risk cancer patients with febrile neutropenia: A useful alternative to the multinational association for supportive care in cancer score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21811253" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28041827" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29168032" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21363878" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4518300" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pneumonia in acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4518300" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pneumonia in acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15201227" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15495074" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17848376" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21556875" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Risk factors for infection and treatment outcome of extended-spectrumβ-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24603001" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Impact of Eastern Cooperative Oncology Group Performance Status on hospital mortality in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460379" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
